Antiglucocorticoid therapy for the prevention of neurological damage in premature infants

a technology of antiglucocorticoid therapy and premature infants, which is applied in the direction of biocide, drug composition, nervous disorder, etc., can solve the problems of decreased lung capacity and edema, alveoli collapse, and newborns with severe respiratory problems at risk of cld, and achieve the effect of preventing neurological damag

Inactive Publication Date: 2005-04-14
CORCEPT THERAPEUTICS INC
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] Accordingly, the present invention provides a method for preventing neurological damage in ventilator-dependent low birth weight preterm infants receiving postnatal glucocorticoid therapy. The method comprises concomitant administration of glucocorticoid receptor antagonists with postnatal glucocorticoids.

Problems solved by technology

CLD is a common complication in premature infants having RDS, although any newborn with severe respiratory problems is at risk for CLD.
Lack of surfactant leads to alveoli collapse, decreased lung capacity and edema.
The inflammation and injury leads to delayed pulmonary growth and development.
Thus, despite the success of glucocorticoid therapy for treating pulmonary inflammation in ventilator-dependent low birth weight preterm infants, there are growing concerns regarding the short and long term adverse effects experienced by glucocorticoid treated premature infants.
The long term neurological disorders are however, the most disconcerting adverse effects.
Thus, while glucocorticoid therapy is a rapid and effective treatment for inflammation, the potential risk for permanent neurological damage threatens to eliminate this promising treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preventing Neurological Damage in a Subject Using Mifepristone

[0087] The following example demonstrates how to practice the methods of the invention.

[0088] Patient Selection:

[0089] Ventilator-dependent low birth weight preterm infants 0-14 days old in need of glucocorticoid therapy using the methods described herein.

[0090] Dosage Regimen and Intrathecal Administration of Mifepristone Concomitantly with Glucocorticoid Therapy:

[0091] The glucocorticoid receptor (GR) antagonist, mifepristone, is used concomitantly with the glucocorticoid dexamethasone in this study. Glucocorticoid therapy is initiated at 0-14 days of age, with dexamethasone being administered intravenously at a dose of about 500 μg / kg / day for approximately 5 days.

[0092] Mifepristone administration is initiated intrathecally within approximately 15 minutes of the start of glucocorticoid therapy, at a dose that is 1000-fold lower than the dosage of the postnatal dexamethasone. At this dosage, mifepristone will bloc...

example 2

Measuring Levels of Glucocorticoid or Antiglucocorticoid in Cerebrospinal Fluid

[0095] The concentration of glucocorticoids or antiglucocorticoids in the cerebrospinal fluid of the infants of Example 1 will be tested before initiation of postnatal glucocorticoid therapy, immediately after initiation of postnatal glucocorticoid therapy, and as necessary during the course of postnatal glucocorticoid therapy and administration of antiglucocorticoid. A lumbar reservoir is surgically implanted into the lower back to sample cerebrospinal fluid and to administer the antiglucocorticoid into the cerebrospinal fluid.

[0096] Samples of cerebrospinal fluid will be tested for the absence or presence and of glucocorticoids and antiglucocorticoids in the cerebrospinal fluid and to measure the concentration of glucocorticoids and antiglucocorticoids when present. Methods for measuring the presence and concentration of glucocorticoids and antiglucocorticoids in samples are well known in the art. For...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
birth weightaaaaaaaaaa
birth weightaaaaaaaaaa
birth weightaaaaaaaaaa
Login to view more

Abstract

This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60 / 489,601, filed Jul. 23, 2003.FIELD OF THE INVENTION [0002] This invention is directed to a method for preventing neurological damage in a ventilator-dependant low birth weight preterm infant in need of postnatal glucocorticoid therapy. BACKGROUND OF THE INVENTION [0003] Low birth weight (less than 2500 grams) accounts for seven percent of all births in the United States and is the most important factor associated with infant mortality (National Center for Health Statistics, Healthy People 2000: Maternal and Infant Heath Progress Review, 1999). [0004] Chronic lung disease (CLD), also known as bronchopulmonary dysplasia is a frequent and increasing complication in premature infants, usually presenting within the first 4 weeks after birth. The incidence and severity of CLD is inversely proportional to gestational age. Along with respiratory...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61KA61K31/235A61K31/56A61K31/567A61K31/569A61K31/573A61K31/59A61K45/06
CPCA61K31/56A61K31/567A61K31/569A61K31/573A61K45/06A61P25/00A61K2300/00
Inventor BELANOFF, JOSEPH
Owner CORCEPT THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap